[go: up one dir, main page]

DK1487840T3 - Krystallinsk polymorf form af irinotecan hydrochlorid - Google Patents

Krystallinsk polymorf form af irinotecan hydrochlorid

Info

Publication number
DK1487840T3
DK1487840T3 DK03743335T DK03743335T DK1487840T3 DK 1487840 T3 DK1487840 T3 DK 1487840T3 DK 03743335 T DK03743335 T DK 03743335T DK 03743335 T DK03743335 T DK 03743335T DK 1487840 T3 DK1487840 T3 DK 1487840T3
Authority
DK
Denmark
Prior art keywords
polymorphic form
irinotecan hydrochloride
crystalline polymorphic
crystalline
irinotecan
Prior art date
Application number
DK03743335T
Other languages
Danish (da)
English (en)
Inventor
Romualdo Forino
Natale Barbugian
Massimo Zampieri
Attilio Tomasi
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of DK1487840T3 publication Critical patent/DK1487840T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DK03743335T 2002-03-01 2003-02-26 Krystallinsk polymorf form af irinotecan hydrochlorid DK1487840T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36068402P 2002-03-01 2002-03-01
PCT/EP2003/001948 WO2003074527A1 (fr) 2002-03-01 2003-02-26 Forme polymorphique cristalline de chlorhydrate d'irinotecan

Publications (1)

Publication Number Publication Date
DK1487840T3 true DK1487840T3 (da) 2007-07-16

Family

ID=27789001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03743335T DK1487840T3 (da) 2002-03-01 2003-02-26 Krystallinsk polymorf form af irinotecan hydrochlorid

Country Status (23)

Country Link
EP (1) EP1487840B1 (fr)
JP (1) JP2005525367A (fr)
KR (1) KR20040091083A (fr)
CN (1) CN1276923C (fr)
AR (1) AR038618A1 (fr)
AT (1) ATE364610T1 (fr)
AU (1) AU2003215594A1 (fr)
BR (1) BR0308133A (fr)
CA (1) CA2477926A1 (fr)
DE (1) DE60314378T2 (fr)
DK (1) DK1487840T3 (fr)
ES (1) ES2287495T3 (fr)
IL (1) IL163820A0 (fr)
MX (1) MXPA04008484A (fr)
NO (1) NO20044138L (fr)
NZ (1) NZ534999A (fr)
PE (1) PE20030923A1 (fr)
PL (1) PL372318A1 (fr)
PT (1) PT1487840E (fr)
RU (1) RU2300535C2 (fr)
TW (1) TWI270374B (fr)
WO (1) WO2003074527A1 (fr)
ZA (1) ZA200406927B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418970C (zh) * 2003-02-25 2008-09-17 株式会社益力多本社 伊立替康盐酸盐的同质多晶的制造方法
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
BRPI0515832A (pt) 2004-12-21 2008-08-05 Sigma Tau Ind Farmaceuti processo estereosseletivo e formas cristalinas de uma camptotecina
CA2591081C (fr) 2005-02-07 2014-10-28 Fermion Oy Procede de fabrication de camptothecine 7-ethyl-10-hydroxy
PL1846371T3 (pl) 2005-02-08 2014-01-31 Fermion Oy Sposób otrzymywania chlorku [1,4']-bipiperydynylo-1'-karbonylu lub jego chlorowodorku
ES2437573T3 (es) * 2005-02-08 2014-01-13 Fermion Oy Procedimiento para la preparación de hidrocloruro de irinotecan
JP5119153B2 (ja) 2005-09-20 2013-01-16 シノファーム シンガポール ピーティーイー，リミテッド イリノテカン塩酸塩の新規結晶形
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
CN101659667B (zh) * 2009-09-07 2011-11-02 重庆泰濠制药有限公司 一种盐酸伊立替康的纯化方法
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102866126B (zh) * 2011-07-05 2016-03-23 重庆华邦制药有限公司 一种定量测定化合物中晶型比例的方法
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
RU2529831C2 (ru) * 2012-11-30 2014-09-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) Способ лечения рака толстой кишки
MX375557B (es) 2014-07-18 2025-03-06 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
US10919905B2 (en) 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules

Also Published As

Publication number Publication date
PL372318A1 (en) 2005-07-11
IL163820A0 (en) 2005-12-18
BR0308133A (pt) 2005-01-04
ES2287495T3 (es) 2007-12-16
DE60314378D1 (en) 2007-07-26
ZA200406927B (en) 2006-06-28
RU2004129307A (ru) 2005-04-10
TW200303753A (en) 2003-09-16
KR20040091083A (ko) 2004-10-27
NZ534999A (en) 2007-03-30
PE20030923A1 (es) 2003-10-29
HK1075044A1 (en) 2005-12-02
NO20044138L (no) 2004-11-29
WO2003074527A1 (fr) 2003-09-12
TWI270374B (en) 2007-01-11
CN1276923C (zh) 2006-09-27
AR038618A1 (es) 2005-01-19
PT1487840E (pt) 2007-09-11
CA2477926A1 (fr) 2003-09-12
DE60314378T2 (de) 2008-02-28
EP1487840B1 (fr) 2007-06-13
AU2003215594A1 (en) 2003-09-16
JP2005525367A (ja) 2005-08-25
ATE364610T1 (de) 2007-07-15
EP1487840A1 (fr) 2004-12-22
RU2300535C2 (ru) 2007-06-10
CN1642958A (zh) 2005-07-20
MXPA04008484A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
DK1487840T3 (da) Krystallinsk polymorf form af irinotecan hydrochlorid
DK1730151T4 (da) Fremgangsmåde til fremstilling af oxycodonhydrochlorid med mindre end 25 ppm 14-hydroxycodeinon
IS7007A (is) Kristallaform af asiþrómýsíni
DK2003136T3 (da) Fremgangsmåde til fremstilling af prasugrel hydrochlorid af høj renhed
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1487832T3 (da) Krystallinsk mikronisat af tiotropiumbromid
DK1682542T3 (da) Nyt krystallinsk anhydrat med anticholinerg effekt
DK1432683T3 (da) Hidtil ukendte krystallinske polymorfe former af lercanidipinhydrochlorid og fremgangsmåder til fremstilling heraf
IL192360A0 (en) Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
IL176141A0 (en) Crystalline forms of valacyclovir hydrochloride
AU2003245029A1 (en) Novel crystalline forms of donepezil hydrochloride
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
ITMI20031333A0 (it) Processo di preparazione di raloxifene cloridrato
AU2003245027A1 (en) Novel crystalline forms of ziprasidone hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
EP1773339A4 (fr) Forme cristalline d'hydrochlorure de donepezil
IL175514A0 (en) Polymorphic form b2 of ziprasidone base
PL373788A1 (en) Novel crystalline forms of gatifloxacin
AU2003248657A1 (en) Polymorphic form xvi of fexofenadine hydrochloride
IL170350A (en) Method for preparing polymorphism of irinotecan hydrochloride
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer
DK2253619T3 (da) Aminsalt af carbostyrilderivat
IL166592A0 (en) Novel crystalline forms of gatifloxacin
DK1685104T3 (da) Fremgangsmåde til fremstilling af N-substituerede phthalomider